公开(公告)号：US20230203000A1

公开(公告)日：2023-06-29

申请号：US18071153

申请日：2022-11-29

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： Leslie A. DAKIN ,  Michael A. BRODNEY ,  Kevin B. DANIEL ,  Elena DOLGIKH ,  Pedro M. GARCIA BARRANTES ,  Ales MEDEK ,  Jessica H. OLSEN ,  Timothy J. SENTER ,  Akira J. SHIMIZU ,  Steven D. STONE ,  Charlene TSAY

IPC: C07D401/04 ,  C07D401/14 ,  C07D405/14

CPC classification number: C07D401/04 ,  C07D401/14 ,  C07D405/14

Abstract: The disclosure provides at least one compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of Formula I, tautomers thereof, deuterated derivatives of those compounds or tautomers, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and/or non-diabetic kidney disease (NDKD).

公开(公告)号：US20250163021A1

公开(公告)日：2025-05-22

申请号：US18836463

申请日：2023-02-08

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： Timothy J. SENTER ,  Leslie A. DAKIN ,  Elena DOLGIKH ,  Jessica H. OLSEN ,  Akira J. SHIMIZU ,  Steven D. STONE

IPC: C07D401/06 ,  A61K31/454 ,  C07D409/14

Abstract: The disclosure provides at least one compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of Formula I, tautomers thereof, deuterated derivatives of those compounds or tautomers, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and/or non-diabetic kidney disease (NDKD).

公开(公告)号：US20250136612A1

公开(公告)日：2025-05-01

申请号：US18836407

申请日：2023-02-08

Applicant: VERTEX PHARMACEUTICALS INCORPORATED

Inventor： Timothy J. SENTER ,  Samantha ANGLE ,  Michael A. BRODNEY ,  Jingrong CAO ,  Jon COME ,  Leslie A. DAKIN ,  Elena DOLGIKH ,  Zachary GALE-DAY ,  Elaine B. KRUEGER ,  Suganthini NANTHAKUMAR ,  Jessica H. OLSEN ,  Akira J. SHIMIZU ,  Steven D. STONE ,  Haoxuan WANG

IPC: C07D495/20 ,  A61K31/438 ,  A61K31/444 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506

Abstract: The disclosure provides at least one compound, tautomer, deuterated derivative, or pharmaceutically acceptable salt chosen from compounds of Formula I, tautomers thereof, deuterated derivatives of those compounds or tautomers, and pharmaceutically acceptable salts of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and/or non-diabetic kidney disease (NDKD).